Mursla Bio
- Diagnostics
- Medical device or technology
- Digital health
Mursla Bio, a leader in extracellular vesicle (EV) science, is a biotech company based in the UK and Boston, MA, on a mission to significantly improve cancer outcomes for at-risk patients.
Powered by the first-in-class organ-specific EV isolation from blood, the Company’s AI Precision Medicine Platform enables the longitudinal generation of intact, organ-specific, and biologically labeled multiomic datasets without requiring large blood volumes or destructive workflows. The platform is full-stack from biomarker discovery to assay development.
Mursla Bio's flagship product, EvoLiver™, was built on this foundation for liver cancer surveillance and recently received the first FDA Breakthrough Device Designation in over 5 years for this indication.
Mursla Bio is advancing plans for a US launch of EvoLiver™ as a Laboratory Developed Test (LDT) in the US and is open for strategic collaborations in companion diagnostics and therapeutic monitoring.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}